Cargando…
Reduced T-cell Numbers and Elevated Levels of Immunomodulatory Cytokines in Metastatic Prostate Cancer Patients De Novo Resistant to Abiraterone and/or Enzalutamide Therapy
Currently, there are two Food and Drug Administration (FDA)-approved drugs for androgen deprivation therapy (ADT) of metastatic castration-resistant prostate cancer (mCRPC) patients: abiraterone and enzalutamide. However, our understanding of the effect of these therapies on the immune system in mCR...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6515443/ https://www.ncbi.nlm.nih.gov/pubmed/31013891 http://dx.doi.org/10.3390/ijms20081831 |
_version_ | 1783418093278593024 |
---|---|
author | Pal, Sumanta K. Moreira, Dayson Won, Haejung White, Seok Woon Duttagupta, Pryanka Lucia, Marc Jones, Jeremy Hsu, JoAnn Kortylewski, Marcin |
author_facet | Pal, Sumanta K. Moreira, Dayson Won, Haejung White, Seok Woon Duttagupta, Pryanka Lucia, Marc Jones, Jeremy Hsu, JoAnn Kortylewski, Marcin |
author_sort | Pal, Sumanta K. |
collection | PubMed |
description | Currently, there are two Food and Drug Administration (FDA)-approved drugs for androgen deprivation therapy (ADT) of metastatic castration-resistant prostate cancer (mCRPC) patients: abiraterone and enzalutamide. However, our understanding of the effect of these therapies on the immune system in mCRPC patients remains limited. Here, we examined how abiraterone and enzalutamide treatment affects levels of soluble immune mediators in plasma and in circulating immune cells of 44 mCRPC patients. We found that the baseline levels of cytokines fibroblast growth factor (FGF), granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin 10 (IL-10), and IL-6 were significantly lower in ADT-sensitive compared to de novo resistant patients. In addition, resistant patients showed significantly lower T cell frequencies. When comparing the levels of cytokines over the course of treatment, we observed that the levels of proinflammatory mediators, such as interferon-γ (IFN-γ), IL-5, macrophage inflammatory protein 1 alpha (MIP-1α), and tumor necrosis factor alpha (TNFα), were significantly increased in the ADT-sensitive patients. At the same time, the abiraterone/enzalutamide therapy did not reduce the percentage of tolerogenic myeloid cell populations, such as polymorphonuclear myeloid-derived suppressor cells, which retained unaltered expression of programmed death-ligand 1 (PD-L1) and B7-H3. Overall, our results suggest that certain immune markers, such as IL-6 and the frequency of effector T cells, could be predictive of therapeutic response to ADT therapies in mCRPC patients. |
format | Online Article Text |
id | pubmed-6515443 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-65154432019-05-30 Reduced T-cell Numbers and Elevated Levels of Immunomodulatory Cytokines in Metastatic Prostate Cancer Patients De Novo Resistant to Abiraterone and/or Enzalutamide Therapy Pal, Sumanta K. Moreira, Dayson Won, Haejung White, Seok Woon Duttagupta, Pryanka Lucia, Marc Jones, Jeremy Hsu, JoAnn Kortylewski, Marcin Int J Mol Sci Article Currently, there are two Food and Drug Administration (FDA)-approved drugs for androgen deprivation therapy (ADT) of metastatic castration-resistant prostate cancer (mCRPC) patients: abiraterone and enzalutamide. However, our understanding of the effect of these therapies on the immune system in mCRPC patients remains limited. Here, we examined how abiraterone and enzalutamide treatment affects levels of soluble immune mediators in plasma and in circulating immune cells of 44 mCRPC patients. We found that the baseline levels of cytokines fibroblast growth factor (FGF), granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin 10 (IL-10), and IL-6 were significantly lower in ADT-sensitive compared to de novo resistant patients. In addition, resistant patients showed significantly lower T cell frequencies. When comparing the levels of cytokines over the course of treatment, we observed that the levels of proinflammatory mediators, such as interferon-γ (IFN-γ), IL-5, macrophage inflammatory protein 1 alpha (MIP-1α), and tumor necrosis factor alpha (TNFα), were significantly increased in the ADT-sensitive patients. At the same time, the abiraterone/enzalutamide therapy did not reduce the percentage of tolerogenic myeloid cell populations, such as polymorphonuclear myeloid-derived suppressor cells, which retained unaltered expression of programmed death-ligand 1 (PD-L1) and B7-H3. Overall, our results suggest that certain immune markers, such as IL-6 and the frequency of effector T cells, could be predictive of therapeutic response to ADT therapies in mCRPC patients. MDPI 2019-04-13 /pmc/articles/PMC6515443/ /pubmed/31013891 http://dx.doi.org/10.3390/ijms20081831 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Pal, Sumanta K. Moreira, Dayson Won, Haejung White, Seok Woon Duttagupta, Pryanka Lucia, Marc Jones, Jeremy Hsu, JoAnn Kortylewski, Marcin Reduced T-cell Numbers and Elevated Levels of Immunomodulatory Cytokines in Metastatic Prostate Cancer Patients De Novo Resistant to Abiraterone and/or Enzalutamide Therapy |
title | Reduced T-cell Numbers and Elevated Levels of Immunomodulatory Cytokines in Metastatic Prostate Cancer Patients De Novo Resistant to Abiraterone and/or Enzalutamide Therapy |
title_full | Reduced T-cell Numbers and Elevated Levels of Immunomodulatory Cytokines in Metastatic Prostate Cancer Patients De Novo Resistant to Abiraterone and/or Enzalutamide Therapy |
title_fullStr | Reduced T-cell Numbers and Elevated Levels of Immunomodulatory Cytokines in Metastatic Prostate Cancer Patients De Novo Resistant to Abiraterone and/or Enzalutamide Therapy |
title_full_unstemmed | Reduced T-cell Numbers and Elevated Levels of Immunomodulatory Cytokines in Metastatic Prostate Cancer Patients De Novo Resistant to Abiraterone and/or Enzalutamide Therapy |
title_short | Reduced T-cell Numbers and Elevated Levels of Immunomodulatory Cytokines in Metastatic Prostate Cancer Patients De Novo Resistant to Abiraterone and/or Enzalutamide Therapy |
title_sort | reduced t-cell numbers and elevated levels of immunomodulatory cytokines in metastatic prostate cancer patients de novo resistant to abiraterone and/or enzalutamide therapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6515443/ https://www.ncbi.nlm.nih.gov/pubmed/31013891 http://dx.doi.org/10.3390/ijms20081831 |
work_keys_str_mv | AT palsumantak reducedtcellnumbersandelevatedlevelsofimmunomodulatorycytokinesinmetastaticprostatecancerpatientsdenovoresistanttoabirateroneandorenzalutamidetherapy AT moreiradayson reducedtcellnumbersandelevatedlevelsofimmunomodulatorycytokinesinmetastaticprostatecancerpatientsdenovoresistanttoabirateroneandorenzalutamidetherapy AT wonhaejung reducedtcellnumbersandelevatedlevelsofimmunomodulatorycytokinesinmetastaticprostatecancerpatientsdenovoresistanttoabirateroneandorenzalutamidetherapy AT whiteseokwoon reducedtcellnumbersandelevatedlevelsofimmunomodulatorycytokinesinmetastaticprostatecancerpatientsdenovoresistanttoabirateroneandorenzalutamidetherapy AT duttaguptapryanka reducedtcellnumbersandelevatedlevelsofimmunomodulatorycytokinesinmetastaticprostatecancerpatientsdenovoresistanttoabirateroneandorenzalutamidetherapy AT luciamarc reducedtcellnumbersandelevatedlevelsofimmunomodulatorycytokinesinmetastaticprostatecancerpatientsdenovoresistanttoabirateroneandorenzalutamidetherapy AT jonesjeremy reducedtcellnumbersandelevatedlevelsofimmunomodulatorycytokinesinmetastaticprostatecancerpatientsdenovoresistanttoabirateroneandorenzalutamidetherapy AT hsujoann reducedtcellnumbersandelevatedlevelsofimmunomodulatorycytokinesinmetastaticprostatecancerpatientsdenovoresistanttoabirateroneandorenzalutamidetherapy AT kortylewskimarcin reducedtcellnumbersandelevatedlevelsofimmunomodulatorycytokinesinmetastaticprostatecancerpatientsdenovoresistanttoabirateroneandorenzalutamidetherapy |